Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIFRA
2024-518987-11-00Phase 2Authorised
- Sponsor
- Istituto Nazionale Tumori IRCCS Fondazione Pascale
- Start
- Nov 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab, irinotecan, fluorouracil and folinic acid in colorectal cancer (CRC), sponsored by Istituto Nazionale Tumori IRCCS Fondazione Pascale. Primary endpoint: Activity assessed by RECIST criteria version 1.1. Planned start Nov 2024; status: authorised.
02
Drugs
cetuximabirinotecanfluorouracilfolinic acid
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2024-518987-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518987-11-00.